Effect of Teriparatide on Bone Formation in the Human Femoral Neck

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

To study the effects of TPTD on the proximal femur, the researchers performed a double-blind trial of TPTD vs placebo (PBO) in patients with osteoarthritis from whom femoral neck (FN) samples were obtained at total hip replacement (THR) surgery.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

Participants were randomly assigned to receive TPTD or PBO for an average of 40 days before THR.

Double tetracycline labeling was initiated 21 days prior to THR to allow histomorphometric assessment of bone formation.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

Serum levels of bone turnover markers were measured at baseline and during the THR.

Standard histomorphometric parameters were measured and calculated on four bone envelopes (cancellous, endocortical, intracortical, and periosteal).

The primary outcome measure was bone formation rate/bone surface (BFR/BS).

What Was Measured

The subject headings attached to it are Bone Density Conservation Agents, Femur Neck, Insulin Resistance, Osteogenesis, Osteoporosis, Postmenopausal and Teriparatide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Teriparatide compound page, all human trials.